The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | P | Antiparasitic products, insecticides and repellents | |
| 2 | P01 | Antiprotozoals | |
| 3 | P01A | Agents against amoebiasis and other protozoal diseases | |
| 4 | P01AX | Other agents against amoebiasis and other protozoal diseases | |
| 5 | P01AX06 | Atovaquone |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 2.25 g |
| Active Ingredient | Description | |
|---|---|---|
| Atovaquone |
Atovaquone is a selective and potent inhibitor of the eukaryotic mitochondrial electron transport chain in a number of parasitic protozoa and the parasitic fungus P. jiroveci. The site of action appears to be the cytochrome bc1 complex (complex III). |
| Title | Information Source | Document Type | |
|---|---|---|---|
| MEPRON Oral suspension | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| WELLVONE Oral suspension | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
